



BADBIR Newsletter February 2014

Thanks to the team at Royal Liverpool and Broadgreen University Hospitals NHS Trust (pictured right) who recruited the most patients to BADBIR in January along with Belfast Health & Social Care Trust



Medical Problems Patient Questionnaire

Please discuss the responses on the medical problems questionnaire with the patient and ensure that these are appropriately reflected on the Adverse Event and Concomitant Therapy page.

If there is a discrepancy please explain in the **Feedback / Comments** section *e.g.* patient ticked admitted to hospital but after discussion it was found not to be an overnight stay, the patient visited A&E with chest pains, this has been added as an adverse event.

| 1. | How many times have you been ADMITTED | to hospital in the since |
|----|---|--------------------------|
| | your last dermatology clinic visit? | None |
| | (Please tick one box) | One |
| | | Two |
| | | More than two |
| 2. | How many NEW DRUGS have you been prescribed since | |
| | your last dermatology clinic visit? | None |
| | (by your GP or the hospital) | One |
| | | Two |
| | | More than two |
| 3. | How many NEW hospital clinics have you been REFERRED to since | |
| | your last dermatology clinic visit? | None |
| | | One |
| | | Two |
| | | More than two |

BADBIR 100 Club Members



We would like to welcome Oxford University Hospitals NHS Trust into the BADBIR 100 Club! Oxford recruited their 100th BADBIR patient in January 2014.

Database Entry — **Biologic Therapy**


Please enter all doses of ustekinumab the patient has received since their last BADBIR follow-up

To add doses for Ustekinumab:

- Biologic therapy changes

Have there been any changes to the patient's biologic therapy details in this follow-up period? No < Click No Yes (use 'Add New' to enter details after clicking 'Update') and Update Update -Show All 💌 entries Drug Start Date Stop Date Frequency Dose 🗘 07/04/2010 Ustekinumab 90 ma N/A Edit Click Edit

Showing 1 to 1 of 1 entries



UV Therapy

Please could all centres provide the patients' **Fitzpatrick Skin Type** and as much information as possible on previous/current exposure to UV therapy. This information is vital in evaluating one of the important study outcomes—

skin <mark>cancer</mark> risk